The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers.
The award will help fund development of the firm's "ksim" algorithm to determine infection relatedness in suspected hospital-acquired infection outbreaks.
One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to develop a point-of-care diagnostic platform for infectious disease.
Nasdaq told the company that its shares have failed to meet a minimum $1 per share closing price for 30 consecutive days and may face delisting action.
The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.
iCubate said that it now has a comprehensive solution within European markets for the detection of bloodstream bacteria and important resistance markers.
The closure has no impact on the firm's other Los Gatos location, the original home of GeneWeave Biosciences, which Roche acquired in 2015 for up to $425 million.
With funding from the Bill and Melinda Gates Foundation, the Biohub will help implement metagenomic sequencing for infectious disease projects in 10 countries.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
